Walt Disney To Invest $30 Billion In Its Theme Parks
Walt Disney Co. (DIS) is planning to invest $30 billion U.S. to upgrade and grow its theme parks in Florida and California.Disney Chief Executive Officer (CEO) Bob Iger says the company plans on “investing more than $30 billion in our theme parks in Florida and California to enhance our offerings, create jobs, and support the U.S. economy.” The big investment comes as Disney faces competition from Universal Studios’ new Florida theme park called Epic Universe, and the addition of the “World of Nintendo” rides at Universal Studios Hollywood in California.Disney plans to spend the $30 billion U.S. over the next decade, though what exactly the investment entails is not yet known. Analysts were quick to characterize the amount of money being spent on Disney’s theme parks and the timeline for the investment as “aggressive.”Iger has made it clear that Disney’s theme parks are a priority and a never-ending investment for the entertainment giant. Both Disneyland in California and Disney World in Florida became a drag on the company’s earnings during the Covid-19 pandemic when they were forced to close or operate at reduced capacity.However, the theme parks are again growth engines for Disney, and CEO Iger says the company plans to ensure their continued success through investments. “Our focus must always be on building for tomorrow, as much as it is on managing for today,” he said.DIS stock has risen 9% this year and currently trades at $120.37 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


